Literature DB >> 8321843

Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.

S L Bramer1, M G Wientjes, J L Au.   

Abstract

This study explored the rectal route of administration for 2',3'-dideoxyinosine (ddI). Rats were given a rectal infusion of nonradiolabeled ddI (200 mg/kg in 0.7 mL saline) over 35 min along with an intravenous (iv) bolus injection of [8-(3)H]ddI (20 microCi, equivalent to 2.1 micrograms), which was used to calculate the absolute rectal bioavailability of ddI. Maximal plasma concentrations of rectally administered unlabeled ddI were 5.4 +/- 2.2 micrograms/mL and were reached at the end of the infusion. The rectal bioavailability averaged 15.6 +/- 4.4% (n = 9). The second aim of this study was to examine the kinetics of ddI absorption from the colorectal region. Analyses of the absorption rate-time profiles by the Loo-Riegelman and deconvolution methods showed biphasic absorption: a rapid phase during infusion and a slow phase postinfusion. These profiles were inconsistent with a mammillary model with absorption from a single site with one apparent rate constant. The model which gave the best fit for infusion and postinfusion data consisted of two different sites (colon and rectum) with different apparent absorption rate constants. The two sites were connected by a first-order transfer of drug solution from rectum to colon. The apparent absorption rate constant in the rectum was 39-fold higher than that in the colon. In conclusion, these results show absorption of ddI from the colorectal region and suggest the rectal route as an alternative to the oral route. The data further suggest different absorption sites in the colorectal region, with a more rapid absorption in the rectum than in the colon.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321843     DOI: 10.1023/a:1018928320449

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  Efficiency of different criteria for selecting pharmacokinetic multiexponential equations.

Authors:  B P Imbimbo; P Martinelli; M Rocchetti; G Ferrari; G Bassotti; E Imbimbo
Journal:  Biopharm Drug Dispos       Date:  1991-03       Impact factor: 1.627

2.  Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K S Marczyk; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

3.  Estimation of drug absorption rates using a deconvolution method with nonequal sampling times.

Authors:  K Iga; Y Ogawa; T Yashiki; T Shimamoto
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

4.  Avoidance of first pass elimination of propranolol after rectal administration to rats.

Authors:  A G de Boer; J M Gubbens-Stibbe; D D Breimer
Journal:  J Pharm Pharmacol       Date:  1981-01       Impact factor: 3.765

5.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

6.  Rectal bioavailability of lidocaine in man: partial avoidance of "first-pass" metabolism.

Authors:  A G de Boer; D D Breimer; H Mattie; J Pronk; J M Gubbens-Stibbe
Journal:  Clin Pharmacol Ther       Date:  1979-12       Impact factor: 6.875

7.  Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K M Wyvill; K P Flora; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1991-09       Impact factor: 6.875

8.  Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Authors:  C A Knupp; W C Shyu; R Dolin; F T Valentine; C McLaren; R R Martin; K A Pittman; R H Barbhaiya
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

9.  Avoidance of "first-pass" elimination of rectally administered lidocaine in relation to the site of absorption in rats.

Authors:  L G de Leede; A G de Boer; C P Roozen; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1983-04       Impact factor: 4.030

10.  Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration.

Authors:  S L Bramer; L C Gunnarsson; J L Au
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

View more
  5 in total

1.  Extensive absorption of 2',3'-dideoxyinosine by intratracheal administration in rats.

Authors:  X Gao; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

2.  Suramin as a chemosensitizer: oral pharmacokinetics in rats.

Authors:  Adam Ogden; M Guillaume Wientjes; Jessie L S Au
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

3.  Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients.

Authors:  U Wintergerst; B Rolinski; B Sölder; J R Bogner; E Wolf; H Jäger; A A Roscher; B H Belohradsky
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

4.  Percutaneous absorption of 2',3'-dideoxyinosine in rats.

Authors:  E Mukherji; N J Millenbaugh; J L Au
Journal:  Pharm Res       Date:  1994-06       Impact factor: 4.200

5.  Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats.

Authors:  B D Anderson; M E Morgan; D Singhal
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.